Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma
NCT03652376
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Severe Eosinophilic Asthma
Interventions
DRUG:
Benralizumab
Sponsor
University of Rostock